<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00497146</url>
  </required_header>
  <id_info>
    <org_study_id>M10-030</org_study_id>
    <secondary_id>2007-001689-34</secondary_id>
    <nct_id>NCT00497146</nct_id>
  </id_info>
  <brief_title>The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4</brief_title>
  <acronym>PRIMO</acronym>
  <official_title>The PRIMO Study: Paricalcitol Capsules Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effects of paricalcitol capsules on cardiac structure and function over 48
      weeks in patients with Stage 3/4 chronic kidney disease (CKD) who had left ventricular
      hypertrophy (LVH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who met the inclusion criteria and did not meet any of the exclusion criteria were
      randomized in a 1:1 ratio to each treatment group to receive paricalcitol capsules or
      placebo. A stratified randomization scheme was used to ensure balance among treatment groups
      with respect to country, gender, and baseline renin angiotensin-aldosterone system (RAAS)
      inhibitor use (yes/no).

      Participants who completed the 48-Week Treatment Period could continue on in the ongoing
      Long-term Follow-up Period that was to last 18 months, with study visits at 6 months, 12
      months and 18 months post Treatment Week 48 Visit. Participants did not receive study drug,
      nor were they to have undergone echocardiogram/MRI procedures during the Long-term Follow-up
      Period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Left Ventricular Mass Index (LVMI) Over 48 Weeks Measured by Cardiac Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>The Central Cardiac MRI Core Laboratory (CCL) interpreted and analyzed all cardiac MRI data. Left Ventricular Mass (LVM) was normalized to the participant's height by the following equation to obtain LVMI: LVM (grams) divided by height (meters)^2.7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Mitral Annular Relaxation Velocity (E')</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Diastolic mitral annular relaxation velocity (lateral E wave velocity; E') is a measure of diastolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ratio of Peak E Wave Velocity to Lateral E Wave Velocity (E/E')</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>The ratio of peak E wave velocity to lateral E wave velocity (E/E') is a measure of diastolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in E-wave Deceleration Time (DT)</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>E-wave deceleration time (DT) is a measure of diastolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Isovolumetric Relaxation Time (IVRT)</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Isovolumetric relaxation time (IVRT) is a measure of diastolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Atrial Volume</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Left atrial volume is a measure of diastolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Triiodothyronine (T3)</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Plasma triiodothyronine (T3) is a biological and inflammatory marker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin-6 (IL-6)</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Interleukin-6 (IL-6) is a biological and inflammatory marker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Troponin-T</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Troponin-T is a biological and inflammatory marker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in B-type Natriuretic Peptide (BNP)</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>B-type natriuretic peptide (BNP) is a biological and inflammatory marker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in High Sensitivity C-reactive Protein (hsCRP)</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>High sensitivity C-reactive protein (hsCRP) is a biological and inflammatory marker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Progression of Thoraco-abdominal Aortic Plaque Volume</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Change from baseline to Week 48 in thoraco-abdominal aortic plaque volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Progression of Thoraco-abdominal Aortic Wall Volume</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Change from baseline to Week 48 in thoraco-abdominal aortic wall volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Progression of Aortic Compliance</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Change from baseline to Week 48 in aortic compliance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Progression of Left Ventricular End-systolic Volume Index</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Change from baseline to Week 48 in left ventricular end-systolic volume index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Progression of Left Ventricular End-diastolic Volume Index</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Change from baseline to Week 48 in left ventricular end-diastolic volume index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Progression of Left Ventricular Ejection Fraction</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Change from baseline to Week 48 in left ventricular ejection fraction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">227</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Left Ventricular Hypertrophy</condition>
  <arm_group>
    <arm_group_label>Paricalcitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paricalcitol</intervention_name>
    <description>2 µg capsule</description>
    <arm_group_label>Paricalcitol</arm_group_label>
    <other_name>ABT-358</other_name>
    <other_name>Zemplar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Estimated glomerular filtration rate (GFR) between 15-60 mL/min/1.73 m^2

          -  Serum intact parathyroid hormone (iPTH) value between 50-300 pg/mL

          -  Corrected serum calcium level 8.0-10.0 mg/dL (2.0-2.5 mmol/L)

          -  Phosphorous level less than or equal to 5.2 mg/dL (1.68 mmol/L)

          -  Serum albumin greater than or equal to 3.0 g/dL (30 g/L)

          -  Echocardiogram results of:

               -  Females: Left ventricular (LV) ejection fraction greater than or equal to 50% and
                  septal wall thickness between 11-17 mm; and,

               -  Males: LV ejection fraction greater than or equal to 50% and septal wall
                  thickness between 12-18 mm

          -  If the subject is receiving renin-angiotensin-aldosterone system (RAAS) inhibitors the
             dose must have been stable for greater than one month prior to the Screening Period.
             However, the subject may have switched to different brands but at equivalent doses as
             determined by the study physician during the month prior to the Screening Period.

          -  Subject must have a technically adequate baseline cardiac magnetic resonance imaging
             (MRI).

        Exclusion Criteria:

          -  Subject has previously been on active vitamin D therapy within the four weeks prior to
             the Screening Period

          -  Pregnant or lactating females

          -  Subject is expected to initiate renal replacement therapy within one year

          -  Subject is taking calcitonin, bisphosphonates, cinacalcet, glucocorticoids (except
             topical or inhaled glucocorticoids)

          -  Subject had clinically significant coronary artery disease (CAD) within 3 months prior
             to the Screening Period, defined as either hospitalization for myocardial infarction
             (MI) or unstable angina; new onset angina with positive functional study or coronary
             angiogram revealing stenosis; or coronary revascularization procedure.

          -  Subject had major cardiac valve abnormality linked with LVH and/or diastolic
             dysfunction, defined as either aortic valve area ≤ 1.5 cm^2 or a mean gradient of &gt; 20
             mmHg; or regurgitation lesions; more than moderate mitral regurgitation, or more than
             moderate aortic regurgitation.

          -  Subject had asymmetric septal hypertrophy defined as septal wall thickness/posterior
             wall thickness ratio &gt; 1.5 based on screening echocardiogram.

          -  Subject had a severe cerebrovascular accident (CVA) within the last 3 months (e.g.,
             hemorrhagic) prior to screening.

          -  Subject had full remission from a malignancy for less than 1 year except completely
             excised non-melanoma skin cancer (e.g., basal or squamous carcinoma) or any history of
             bone metastasis.

          -  Subject had comorbid conditions (e.g., advanced malignancy, advanced liver disease)
             with a life expectancy less than 1 year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Eldred, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8062</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8867</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8864</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7257</name>
      <address>
        <city>San Dimas</city>
        <state>California</state>
        <zip>91773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7727</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8861</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7260</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7725</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7824</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 18882</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7823</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7249</name>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <zip>60805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7816</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 18881</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7817</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7245</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7248</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8868</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7828</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 14442</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131-3403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6567</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7262</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7826</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8865</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7261</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8058</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7830</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7825</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157-7000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8866</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7263</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8493</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8506</name>
      <address>
        <city>Liverpool</city>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8507</name>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 9581</name>
      <address>
        <city>Reservoir</city>
        <zip>3073</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 9582</name>
      <address>
        <city>Richmond</city>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8500</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8246</name>
      <address>
        <city>Prague 4</city>
        <zip>14021</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8499</name>
      <address>
        <city>Prague 6</city>
        <zip>16900</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8245</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6692</name>
      <address>
        <city>Dortmund</city>
        <zip>44263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 9723</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40210</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6630</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7268</name>
      <address>
        <city>Nettetal</city>
        <zip>41334</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6622</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 10626</name>
      <address>
        <city>Lido di Camaiore</city>
        <zip>55041</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8070</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8060</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8519</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7702</name>
      <address>
        <city>Humacao</city>
        <zip>00791</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7269</name>
      <address>
        <city>Ponce</city>
        <zip>00717-1322</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7818</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7270</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7712</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7266</name>
      <address>
        <city>Toa Baja</city>
        <zip>00949</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8881</name>
      <address>
        <city>Bucharest</city>
        <zip>010731</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8518</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8514</name>
      <address>
        <city>Iasi</city>
        <zip>700503</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 22682</name>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8009</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7251</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 7250</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8883</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8358</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8355</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8356</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8882</name>
      <address>
        <city>Santander (Cantabria)</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8234</name>
      <address>
        <city>Hsin-Chuang City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8884</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8228</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8229</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 8823</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2007</study_first_submitted>
  <study_first_submitted_qc>July 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2007</study_first_posted>
  <results_first_submitted>September 22, 2011</results_first_submitted>
  <results_first_submitted_qc>November 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2011</results_first_posted>
  <last_update_submitted>March 8, 2013</last_update_submitted>
  <last_update_submitted_qc>March 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>paricalcitol</keyword>
  <keyword>Zemplar</keyword>
  <keyword>PRIMO</keyword>
  <keyword>Chronic Kidney Disease Stage 3B/4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled in the study at US and ex-US investigative sites. Recruitment began in March 2008 and ended in December 2009. The study population consisted of participants with Stage 3/4 chronic kidney disease who had a diagnosis of left ventricular hypertrophy confirmed by echocardiogram and cardiac magnetic resonance imaging.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Paricalcitol</title>
          <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Required dialysis</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change in RAAS inhibitor therapy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to dose reduce per protocol</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long-term Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Paricalcitol</title>
          <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="115"/>
            <count group_id="B2" value="112"/>
            <count group_id="B3" value="227"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.3" spread="11.30"/>
                    <measurement group_id="B2" value="65.7" spread="12.20"/>
                    <measurement group_id="B3" value="65.0" spread="11.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline RAAS Status</title>
          <description>Baseline renin angiotensin-aldosterone system (RAAS) status refers to whether or not (yes/no) the participant was receiving RAAS inhibitor therapy at baseline.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetic Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Type I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at Beginning of Long term Follow-up Period</title>
          <description>Age demographics for the long-term follow-up population include data for 65 and 72 participants in the paricalcitol and placebo groups, respectively.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="11.01"/>
                    <measurement group_id="B2" value="66.5" spread="12.09"/>
                    <measurement group_id="B3" value="65.6" spread="11.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender at Beginning of Long term Follow-up Period</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Left Ventricular Mass Index (LVMI) Over 48 Weeks Measured by Cardiac Magnetic Resonance Imaging (MRI)</title>
        <description>The Central Cardiac MRI Core Laboratory (CCL) interpreted and analyzed all cardiac MRI data. Left Ventricular Mass (LVM) was normalized to the participant's height by the following equation to obtain LVMI: LVM (grams) divided by height (meters)^2.7.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>The analysis was based on the intent-to-treat (ITT) population, defined as all randomized participants who took at least one dose of study drug, with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Left Ventricular Mass Index (LVMI) Over 48 Weeks Measured by Cardiac Magnetic Resonance Imaging (MRI)</title>
          <description>The Central Cardiac MRI Core Laboratory (CCL) interpreted and analyzed all cardiac MRI data. Left Ventricular Mass (LVM) was normalized to the participant's height by the following equation to obtain LVMI: LVM (grams) divided by height (meters)^2.7.</description>
          <population>The analysis was based on the intent-to-treat (ITT) population, defined as all randomized participants who took at least one dose of study drug, with available data.</population>
          <units>grams/meter^2.7</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.248"/>
                    <measurement group_id="O2" value="-0.07" spread="0.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.145</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed model includes treatment, visit, gender, baseline RAAS inhibitor use, country, baseline value, and treatment by visit interaction.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Mitral Annular Relaxation Velocity (E')</title>
        <description>Diastolic mitral annular relaxation velocity (lateral E wave velocity; E') is a measure of diastolic function.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>The intent-to-treat (ITT) population, participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Mitral Annular Relaxation Velocity (E')</title>
          <description>Diastolic mitral annular relaxation velocity (lateral E wave velocity; E') is a measure of diastolic function.</description>
          <population>The intent-to-treat (ITT) population, participants with available data.</population>
          <units>centimeters/second</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.314"/>
                    <measurement group_id="O2" value="-0.30" spread="0.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ratio of Peak E Wave Velocity to Lateral E Wave Velocity (E/E')</title>
        <description>The ratio of peak E wave velocity to lateral E wave velocity (E/E') is a measure of diastolic function.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>The intent-to-treat (ITT) population, participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ratio of Peak E Wave Velocity to Lateral E Wave Velocity (E/E')</title>
          <description>The ratio of peak E wave velocity to lateral E wave velocity (E/E') is a measure of diastolic function.</description>
          <population>The intent-to-treat (ITT) population, participants with available data.</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.580"/>
                    <measurement group_id="O2" value="-0.33" spread="0.601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in E-wave Deceleration Time (DT)</title>
        <description>E-wave deceleration time (DT) is a measure of diastolic function.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>The intent-to-treat (ITT) population, participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in E-wave Deceleration Time (DT)</title>
          <description>E-wave deceleration time (DT) is a measure of diastolic function.</description>
          <population>The intent-to-treat (ITT) population, participants with available data.</population>
          <units>seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.004"/>
                    <measurement group_id="O2" value="-0.00" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Isovolumetric Relaxation Time (IVRT)</title>
        <description>Isovolumetric relaxation time (IVRT) is a measure of diastolic function.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>The intent-to-treat (ITT) population, participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Isovolumetric Relaxation Time (IVRT)</title>
          <description>Isovolumetric relaxation time (IVRT) is a measure of diastolic function.</description>
          <population>The intent-to-treat (ITT) population, participants with available data.</population>
          <units>seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.002"/>
                    <measurement group_id="O2" value="-0.00" spread="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Atrial Volume</title>
        <description>Left atrial volume is a measure of diastolic function.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>The intent-to-treat (ITT) population, participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Atrial Volume</title>
          <description>Left atrial volume is a measure of diastolic function.</description>
          <population>The intent-to-treat (ITT) population, participants with available data.</population>
          <units>milliliters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.94" spread="1.159"/>
                    <measurement group_id="O2" value="-0.92" spread="1.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Triiodothyronine (T3)</title>
        <description>Plasma triiodothyronine (T3) is a biological and inflammatory marker.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>The intent-to-treat (ITT) population, participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Triiodothyronine (T3)</title>
          <description>Plasma triiodothyronine (T3) is a biological and inflammatory marker.</description>
          <population>The intent-to-treat (ITT) population, participants with available data.</population>
          <units>nanomoles/liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.036"/>
                    <measurement group_id="O2" value="0.12" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interleukin-6 (IL-6)</title>
        <description>Interleukin-6 (IL-6) is a biological and inflammatory marker.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>The intent-to-treat (ITT) population, participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin-6 (IL-6)</title>
          <description>Interleukin-6 (IL-6) is a biological and inflammatory marker.</description>
          <population>The intent-to-treat (ITT) population, participants with available data.</population>
          <units>nanograms/liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.844"/>
                    <measurement group_id="O2" value="-0.85" spread="0.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Troponin-T</title>
        <description>Troponin-T is a biological and inflammatory marker.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>The intent-to-treat (ITT) population, participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Troponin-T</title>
          <description>Troponin-T is a biological and inflammatory marker.</description>
          <population>The intent-to-treat (ITT) population, participants with available data.</population>
          <units>micrograms/liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.002"/>
                    <measurement group_id="O2" value="0.00" spread="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in B-type Natriuretic Peptide (BNP)</title>
        <description>B-type natriuretic peptide (BNP) is a biological and inflammatory marker.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>The intent-to-treat (ITT) population, participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in B-type Natriuretic Peptide (BNP)</title>
          <description>B-type natriuretic peptide (BNP) is a biological and inflammatory marker.</description>
          <population>The intent-to-treat (ITT) population, participants with available data.</population>
          <units>log nanograms/liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.086"/>
                    <measurement group_id="O2" value="0.35" spread="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in High Sensitivity C-reactive Protein (hsCRP)</title>
        <description>High sensitivity C-reactive protein (hsCRP) is a biological and inflammatory marker.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>The intent-to-treat (ITT) population, participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in High Sensitivity C-reactive Protein (hsCRP)</title>
          <description>High sensitivity C-reactive protein (hsCRP) is a biological and inflammatory marker.</description>
          <population>The intent-to-treat (ITT) population, participants with available data.</population>
          <units>milligrams/liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="1.658"/>
                    <measurement group_id="O2" value="1.06" spread="1.623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Progression of Thoraco-abdominal Aortic Plaque Volume</title>
        <description>Change from baseline to Week 48 in thoraco-abdominal aortic plaque volume.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>The intent-to-treat (ITT) population, participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Progression of Thoraco-abdominal Aortic Plaque Volume</title>
          <description>Change from baseline to Week 48 in thoraco-abdominal aortic plaque volume.</description>
          <population>The intent-to-treat (ITT) population, participants with available data.</population>
          <units>milliliters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.002"/>
                    <measurement group_id="O2" value="-0.03" spread="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Progression of Thoraco-abdominal Aortic Wall Volume</title>
        <description>Change from baseline to Week 48 in thoraco-abdominal aortic wall volume</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>The intent-to-treat (ITT) population, participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Progression of Thoraco-abdominal Aortic Wall Volume</title>
          <description>Change from baseline to Week 48 in thoraco-abdominal aortic wall volume</description>
          <population>The intent-to-treat (ITT) population, participants with available data.</population>
          <units>milliliters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.023"/>
                    <measurement group_id="O2" value="-0.10" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Progression of Aortic Compliance</title>
        <description>Change from baseline to Week 48 in aortic compliance.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>The intent-to-treat (ITT) population, participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Progression of Aortic Compliance</title>
          <description>Change from baseline to Week 48 in aortic compliance.</description>
          <population>The intent-to-treat (ITT) population, participants with available data.</population>
          <units>10^-4 cm^2/mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.24" spread="5.011"/>
                    <measurement group_id="O2" value="-5.79" spread="4.958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Progression of Left Ventricular End-systolic Volume Index</title>
        <description>Change from baseline to Week 48 in left ventricular end-systolic volume index.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>The intent-to-treat (ITT) population, participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Progression of Left Ventricular End-systolic Volume Index</title>
          <description>Change from baseline to Week 48 in left ventricular end-systolic volume index.</description>
          <population>The intent-to-treat (ITT) population, participants with available data.</population>
          <units>milliliters/meter^2.7</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.420"/>
                    <measurement group_id="O2" value="0.57" spread="0.412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Progression of Left Ventricular End-diastolic Volume Index</title>
        <description>Change from baseline to Week 48 in left ventricular end-diastolic volume index.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>The intent-to-treat (ITT) population, participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Progression of Left Ventricular End-diastolic Volume Index</title>
          <description>Change from baseline to Week 48 in left ventricular end-diastolic volume index.</description>
          <population>The intent-to-treat (ITT) population, participants with available data.</population>
          <units>milliliters/meter^2.7</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.480"/>
                    <measurement group_id="O2" value="-0.36" spread="0.478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Progression of Left Ventricular Ejection Fraction</title>
        <description>Change from baseline to Week 48 in left ventricular ejection fraction.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>The intent-to-treat (ITT) population, participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Progression of Left Ventricular Ejection Fraction</title>
          <description>Change from baseline to Week 48 in left ventricular ejection fraction.</description>
          <population>The intent-to-treat (ITT) population, participants with available data.</population>
          <units>percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="0.773"/>
                    <measurement group_id="O2" value="-0.54" spread="0.771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AE(s) reported from the time of study drug administration until 30 days after last study drug administration were collected (up to 52 weeks). In addition, serious adverse events were collected throughout the 18-month Long-term Follow-up Period.</time_frame>
      <desc>AEs were coded using the MedDRA version 14.0 coding dictionary for AEs collected during the Treatment Period and version 14.1 for AEs collected during the Long-term Follow-up Period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Paricalcitol: Treatment Period</title>
          <description>Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo: Treatment Period</title>
          <description>Participants received 2 placebo capsules once a day for up to 48 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Paricalcitol: Long-term Follow-up</title>
          <description>Participants who received paricalcitol and completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
        </group>
        <group group_id="E4">
          <title>Placebo: Long-term Follow-up</title>
          <description>Participants who received placebo and completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0 / 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Autoimmune thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital cystic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Functional gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Small intestine obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Femoral neck injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Tetany</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Intracranial haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Post-traumatic epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Vesicourteric reflux</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pickwickian syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 14.0 / 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie (prior sponsor, Abbott)</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

